Introduction
Semaglutide has become the most widely recognized peptide therapeutic in the world, driving unprecedented demand for quality testing services. As the active ingredient in Ozempic, Wegovy, and Rybelsus, Semaglutide's popularity in both clinical and research settings has created an urgent need for reliable, independent analytical testing. ACS Peptide Testing Labs provides specialized Semaglutide analysis to ensure sample quality and authenticity.
Understanding Semaglutide
Semaglutide is a 31-amino acid GLP-1 receptor agonist with key modifications that differentiate it from native GLP-1:
Molecular Profile
- Molecular Formula: C187H291N45O59
- Molecular Weight: ~4,113.58 Da
- Key Modifications:
- Half-life: ~7 days (enabling once-weekly injection)
The combination of amino acid substitutions and lipidation makes Semaglutide resistant to enzymatic degradation while enabling albumin binding for extended circulation.
Analytical Testing Methods
HPLC Purity Analysis
Our optimized RP-HPLC method for Semaglutide:
- Column: C4 or C8, 300 angstrom pore size for optimal resolution of lipidated peptides
- Mobile Phase: Water/acetonitrile with 0.1% TFA, shallow gradient
- Detection: UV 214nm (peptide backbone) and 280nm (aromatic residues)
- Resolution: Baseline separation of main peak from related substances
- Typical specification: Greater than or equal to 95% purity for research grade
Mass Spectrometry
Identity confirmation is critical given the prevalence of counterfeit or mislabeled products:
- Intact mass analysis: ESI-MS confirming MW of 4,113.58 Da
- LC-MS/MS sequencing: Confirms amino acid sequence and modification sites
- Key checkpoints: Aib at position 8, Arg34 substitution, C18 fatty diacid at Lys26 with linker
- Deconvolution: MaxEnt or similar algorithms for clean mass determination
Counter-Ion and Salt Form Analysis
Semaglutide is available in different salt forms:
- Acetate salt (most common for research)
- Sodium salt (pharmaceutical formulations)
- Salt form affects net peptide content calculations
- Ion chromatography or potentiometric titration for accurate determination
Common Quality Issues
1. Identity Fraud and Mislabeling
Given Semaglutide's commercial value, we frequently encounter:
- Samples labeled as Semaglutide that contain different peptides entirely
- Liraglutide (a related GLP-1 agonist) substituted for Semaglutide
- Degraded or expired material sold as fresh product
- Mass spectrometry is the definitive tool for detecting these issues
2. Incorrect Lipidation
The C18 fatty diacid with mini-PEG linker at Lys26 is the most challenging synthetic step:
- Partial lipidation (missing or incomplete fatty acid attachment)
- Wrong linker length or structure
- Lipidation at incorrect lysine positions
- Each defect alters pharmacokinetic properties
3. Oxidation and Degradation
Semaglutide contains oxidation-susceptible residues:
- Met(O) formation: Methionine sulfoxide (+16 Da)
- Trp oxidation: Kynurenine and other oxidation products
- Deamidation: Asn and Gln residues converting to Asp/Glu (+1 Da)
- Accelerated by light exposure, elevated temperature, and alkaline pH
4. Aggregation and Fibrillation
Like many GLP-1 analogs, Semaglutide can form:
- Soluble oligomers (detected by SEC-HPLC)
- Amyloid-like fibrils (detected by ThT fluorescence)
- Particulate matter (visual inspection and light obscuration)
- More common at high concentrations and during agitation
